Browsing by Author "Yetkin M.F."

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Re-examining the characteristics of pediatric multiple sclerosis in the era of antibody-associated demyelinating syndromes
    (W.B. Saunders Ltd, 2022) Yılmaz Ü.; Gücüyener K.; Yavuz M.; Öncel İ.; Canpolat M.; Saltık S.; Ünver O.; Çıtak Kurt A.N.; Tosun A.; Yılmaz S.; Özgör B.; Erol İ.; Öztoprak Ü.; Elitez D.A.; Direk M.Ç.; Bodur M.; Teber S.; Anlar B.; Aykol D.; Yıldız E.P.; Yarar C.; Kara B.; Haspolat; İncecik F.; Kutluk G.; Dilber C.; Dundar N.O.; Tan H.; Demir E.; Dursun B.D.; Dilek T.D.; Türkdoğan D.; Yalnızoğlu D.; Akbaş S.; Güleç A.; Yılmaz D.; Ayanoğlu M.; Kanmaz S.; Güngör S.; Öztürk G.; Besen; Haliloğlu G.; Karaca N.B.; Öztürk S.; Yüksel D.; Gürkaş E.; Oktay S.; Serin H.M.; Karadağ M.; Hakkı Akbeyaz İ.; Yiş U.; Polat B.G.; Okan M.S.; Bektaş Ö.; Orgun L.T.; Günbey C.; Per H.; Gültutan P.; Öztürk S.B.; Aksoy E.; Akyüz G.; Tekgül H.; Kürekçi F.; Kurul A.S.H.; Çarman K.B.; Alikılıç D.; Duman Ö.; Kömür M.; Yıldırım M.; Alıcı N.; Gümüş H.; Polat M.; Konuşkan B.; Güngör O.; Mert G.G.; Edizer S.; Mıhçı F.; Öztürk S.T.; Toker R.T.; Arslan M.; Şahin S.; Gencpinar P.; Yıldırım E.; Yüksel E.; Ekici A.; Deniz A.; Yayici Köken Ö.; Okuyaz Ç.; Süt N.Y.; Atasoy E.; Solmaz İ.; Yetkin M.F.; Bilgin N.; Atasever A.K.; Tekin H.G.; Dokurel İ.; Özçelik A.; Aksoy A.; Türköz A.N.; Cavusoglu D.; Özkan M.; Tekin E.; Şahin T.U.; Ünalp A.; Koç H.; Sarıgeçili E.; Sarıtaş S.; Ayça S.; Kayılıoğlu H.; Şenoğlu M.Ç.; Kamaşak T.; Asadova N.; Keskin F.; Karaoğlu P.; İpek R.; Acer H.
    Background: The discovery of anti-myelin oligodendrocyte glycoprotein (MOG)-IgG and anti-aquaporin 4 (AQP4)-IgG and the observation on certain patients previously diagnosed with multiple sclerosis (MS) actually have an antibody-mediated disease mandated re-evaluation of pediatric MS series. Aim: To describe the characteristics of recent pediatric MS cases by age groups and compare with the cohort established before 2015. Method: Data of pediatric MS patients diagnosed between 2015 and 2021 were collected from 44 pediatric neurology centers across Türkiye. Clinical and paraclinical features were compared between patients with disease onset before 12 years (earlier onset) and ≥12 years (later onset) as well as between our current (2015–2021) and previous (<2015) cohorts. Results: A total of 634 children (456 girls) were enrolled, 89 (14%) were of earlier onset. The earlier-onset group had lower female/male ratio, more frequent initial diagnosis of acute disseminated encephalomyelitis (ADEM), more frequent brainstem symptoms, longer interval between the first two attacks, less frequent spinal cord involvement on magnetic resonance imaging (MRI), and lower prevalence of cerebrospinal fluid (CSF)-restricted oligoclonal bands (OCBs). The earlier-onset group was less likely to respond to initial disease-modifying treatments. Compared to our previous cohort, the current series had fewer patients with onset <12 years, initial presentation with ADEM-like features, brainstem or cerebellar symptoms, seizures, and spinal lesions on MRI. The female/male ratio, the frequency of sensorial symptoms, and CSF-restricted OCBs were higher than reported in our previous cohort. Conclusion: Pediatric MS starting before 12 years was less common than reported previously, likely due to exclusion of patients with antibody-mediated diseases. The results underline the importance of antibody testing and indicate pediatric MS may be a more homogeneous disorder and more similar to adult-onset MS than previously thought. © 2022 European Paediatric Neurology Society
  • No Thumbnail Available
    Item
    The role of oligoclonal band count and IgG index in treatment response and disease activity in multiple sclerosis
    (Elsevier B.V., 2024) Taşkıran E.; Terzi M.; Helvacı E.M.; Eser M.Z.; Avcı B.; Ömer Faruk T.; Yetkin M.F.; Çilingir V.; Bir L.S.; Kabay S.C.; Bilge N.; Poyraz T.; Demir C.F.; Dündar D.K.; Ocak Ö.; Çam M.; Mavioğlu H.; Altun Y.; Karaibrahimoğlu A.
    Background/aim: Multiple sclerosis (MS) is an inflammatory demyelinating central nervous system (CNS) disease. Among the paraclinical tests, brain and spinal Magnetic Resonance Imaging (MRI) is primarily involved in the diagnosis process, and cerebrospinal fluid (CSF) analysis is fundamental in diagnosing MS and the differential diagnosis. A positive relationship was demonstrated between oligoclonal band (OCB) positivity, CSF band number and immunoglobulin G(IgG) index. The study aimed to evaluate whether the number of OCB can predict disease activity and determine a correlation with the IgG index. Methods: Our study included 401 MS patients who had relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), clinic isolated syndrome (CIS), radiologic isolated syndrome (RIS), Neuromyelitis optica spectrum disorder (NMOSD) and Acute disseminated encephalomyelitis (ADEM) with OCB number groups of 2–4, 4–8, 8–12, and 12 and above. Results: No significant correlation was observed between IgG index, pre-and post-treatment EDSS (Expanded Disability Status Scale Scores) and disease-modifying therapies (DMT). Drug response was better in the patient group with band number between 2 and 8 and post-treatment EDSS scores were lower (1.62±0.44). Conclusion: The study results suggested that band number may be as valuable as the IgG index and a predictive biomarker for disease activity. © 2023
  • No Thumbnail Available
    Item
    Corrigendum to “Re-examining the characteristics of pediatric multiple sclerosis in the era of antibody-associated demyelinating syndromes” [Europ. J. Paediatr. Neurol. 41 (2022) 8–18 doi.org/10.1016/j.ejpn.2022.08.006, (S1090379822001246), (10.1016/j.ejpn.2022.08.006)]
    (W.B. Saunders Ltd, 2024) Yılmaz Ü.; Gücüyener K.; Yavuz M.; Ibrahim Oncel; Canpolat M.; Saltık S.; Ünver O.; Çıtak Kurt A.N.; Tosun A.; Yılmaz S.; Özgör B.; Ilknur Erol; Öztoprak Ü.; Elitez D.A.; Çobanoğulları Direk M.; Bodur M.; Teber S.; Anlar B.; Erol İ.; Aykol D.; Direk M.Ç.; Yıldız E.P.; Yarar C.; Kara B.; Haspolat; İncecik F.; Kutluk G.; Dilber C.; Dundar N.O.; Tan H.; Öncel İ.; Demir E.; Dursun B.D.; Dilek T.D.; Türkdoğan D.; Yalnızoğlu D.; Akbaş S.; Güleç A.; Yılmaz D.; Ayanoğlu M.; Kanmaz S.; Güngör S.; Öztürk G.; Besen; Haliloğlu G.; Karaca N.B.; Öztürk S.; Yüksel D.; Gürkaş E.; Oktay S.; Serin H.M.; Karadağ M.; Akbeyaz İ.H.; Yiş U.; Polat B.G.; Okan M.S.; Bektaş Ö.; Orgun L.T.; Günbey C.; Per H.; Gültutan P.; Öztürk S.B.; Aksoy E.; Akyüz G.; Tekgül H.; Kürekçi F.; Hız Kurul A.S.; Çarman K.B.; Alikılıç D.; Duman Ö.; Kömür M.; Yıldırım M.; Alıcı N.; Gümüş H.; Polat M.; Konuşkan B.; Güngör O.; Mert G.G.; Edizer S.; Mıhçı F.; Öztürk S.T.; Toker R.T.; Arslan M.; Şahin S.; Gencpinar P.; Yıldırım E.; Yüksel E.; Ekici A.; Deniz A.; Köken Ö.Y.; Okuyaz Ç.; Süt N.Y.; Atasoy E.; Solmaz İ.; Yetkin M.F.; Bilgin N.; Atasever A.K.; Tekin H.G.; Dokurel İ.; Özçelik A.; Aksoy A.; Türköz A.N.; Cavusoglu D.; Özkan M.; Tekin E.; Şahin T.U.; Ünalp A.; Koç H.; Sarıgeçili E.; Sarıtaş S.; Ayça S.; Kayılıoğlu H.; Şenoğlu M.Ç.; Kamaşak T.; Asadova N.; Keskin F.; Karaoğlu P.; İpek R.; Acer H.
    The authors would like to apologise for any inconvenience caused. © 2024 European Paediatric Neurology Society
  • No Thumbnail Available
    Item
    Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein
    (Galenos Publishing House, 2024) Koç S.; Şen S.; Terzi Y.; Kızılay F.; Demir S.; Aksoy D.B.; Kurtuluş F.; Bilge N.; Idilman E.; Uzunköprü C.; Güngör S.; Çilingir V.; Ethemoğlu Ö.; Boz C.; Gümüş H.; Kılıç A.K.; Kısabay A.; Bir L.S.; Turan Ö.F.; Soysal A.; Köseoğlu M.; Uzuner G.T.; Bayındır H.; Kabay S.C.; Çam M.; Yayla V.; Tan H.; Özcan A.; Taşkapıoğlu Ö.; Korkmaz M.; Tamam Y.; İnanç Y.; Efendi H.; Kotan D.; Yetkin M.F.; Bilgiç A.B.; Saçmacı H.; Demirci S.; Çelik Y.; Poyraz T.; Terzi M.
    Background: Optic neuritis, myelitis, and neuromyelitis optica spectrum disorder (NMOSD) have been associated with antibodies against myelin oligodendrocyte glycoprotein-immunoglobulin G (anti-MOG-IgG). Furthermore, patients with radiological and demographic features atypical for multiple sclerosis (MS) with optic neuritis and myelitis also demonstrate antibodies against aquaporin-4 and anti-MOG-IgG. However, data on the diagnosis, treatment, follow-up, and prognosis in patients with anti-MOG-IgG are limited. Aims: To evaluate the clinical, radiological, and demographic characteristics of patients with anti-MOG-IgG. Study Design: Multicenter, retrospective, observational study. Methods: Patients with blood samples demonstrating anti-MOG-IgG that had been evaluated at the Neuroimmunology laboratory at Ondokuz Mayıs University’s Faculty of Medicine were included in the study. Results: Of the 104 patients with anti-MOG-IgG, 56.7% were women and 43.3% were men. Approximately 2.4% of the patients were diagnosed with MS, 15.8% with acute disseminated encephalomyelitis (ADEM), 39.4% with NMOSD, 31.3% with isolated optic neuritis, and 11.1% with isolated myelitis. Approximately 53.1% of patients with spinal involvement at clinical onset demonstrated a clinical course of NMOSD. Thereafter, 8.8% of these patients demonstrated a clinical course similar to MS and ADEM, and 28.1% demonstrated a clinical course of isolated myelitis. The response to acute attack treatment was lower and the disability was higher in patients aged > 40 years than patients aged < 40 years at clinical onset. Oligoclonal band was detected in 15.5% of the patients. Conclusion: For patients with NMOSD and without anti-NMO antibodies, the diagnosis is supported by the presence of anti-MOG-IgG. Furthermore, advanced age at clinical onset, Expanded Disability Status Scale (EDSS) score at clinical onset, spinal cord involvement, and number of attacks may be negative prognostic factors in patients with anti-MOG-IgG. © Author(s).
  • No Thumbnail Available
    Item
    Corrigendum to “The role of oligoclonal band count and IgG index in treatment response and disease activity in multiple sclerosis” [Multiple Sclerosis and Related Disorders 83 (2024) 105391] (Multiple Sclerosis and Related Disorders (2024) 83, (S2211034823008908), (10.1016/j.msard.2023.105391))
    (Elsevier B.V., 2025) Taşkıran E.; Terzi M.; Helvacı E.M.; Eser M.Z.; Avcı B.; Faruk T.Ö.; Yetkin M.F.; Çilingir V.; Bir L.S.; Kabay S.C.; Bilge N.; Poyraz T.; Demir C.F.; Dündar D.K.; Deveci E.E.; Çam M.; Mavioğlu H.; Altun Y.; Karaibrahimoğlu A.
    The authors regret Esra Taşkıran1, Murat Terzi2, Elif Merve Helvacı3, Meltem Zeycan Eser4, Bahattin Avcı5, Turan Ömer Faruk6, Mehmet Fatih Yetkin7, Vedat Çilingir8, Levent Sinan Bir9, Sibel Canbaz Kabay10, Nuray Bilge11, Turan Poyraz12, Caner Feyzi Demir13, Dilcan Kotan Dündar14,Emrah Emre Deveci15, Mustafa Çam16, Hatice Mavioğlu17, Yaşar Altun18, Adnan Karaibrahimoğlu19 1 Antalya Training and Research Hospital Neurology Clinic, Antalya 2 Ondokuz Mayıs University Faculty of Medicine Department of Neurology, Samsun 3 Ondokuz Mayıs University Graduate School of Education Department of Neurosciences, Samsun 4 Ondokuz Mayıs University Department of Biochemistry, Samsun 5 Ondokuz Mayıs University Department of Biochemistry, Samsun 6 Uludag University Faculty of Medicine Department of Neurology, Bursa 7 Erciyes University Faculty of Medicine, Kayseri 8 Van Yüzüncüyıl University Faculty of Medicine, Van 9 Pamukkale University Faculty of Medicine, Denizli 10 Dokuz Eylul University Faculty of Medicine, İzmir 11 Atatürk University Faculty of Medicine, Erzurum 12 Private Medifema Hospital, İzmir 13 Firat University Faculty of Medicine, Elazığ 14 Sakarya University Faculty of Medicine, Sakarya 15 Muğla Sıtkı Koçman University Faculty of Medicine, Muğla 16 Çanakkale University Faculty of Medicine, Çanakkale 17 Celal Bayar University Faculty of Medicine, Manisa 18 Adıyaman University Faculty of Medicine, Adıyaman 19 Süleyman Demirel University Faculty of Medicine, Department of Biostatistics and Medical Informatics, Isparta Unfortunately, due to oversight, an author-related error occurred in the article. In order to facilitate the requested change of author, I have previously forwarded to the editorial manager the necessary documentation, including the signatures of the authors involved. The authors would like to apologise for any inconvenience caused. © 2025 Elsevier B.V.